Filing Flows

Filing Flows › Maze Therapeutics (MAZE) › Next earnings date

Maze Therapeutics (MAZE) earnings on Nov 9, 2026: what to expect

Maze Therapeutics (MAZE) is expected to report earnings on Nov 9, 2026 (estimated), tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.75 (−$0.87 to −$0.56, 10 estimates), against −$0.66 a year ago. It beat the EPS estimate in 67% of the quarters on record; Filing Flows' model gives it a 73% chance of beating next time.

Report dateNov 9, 2026 (estimated)
Days to go1
EPS estimate−$0.75
Beat rate67%

The last report

Maze Therapeutics reported revenue of $20.0M for the first quarter 2026, net loss $24.2M. How it makes money → · Every quarter →

Maze Therapeutics: EPS against the estimate, last 3 reportsMaze Therapeutics: EPS against the estimate, last 3 reportsEstimateReported−$0.69−$0.66Nov 25−$0.69−$0.65Mar 26−$0.70−$0.76Aug 26
Latest (Aug 26): Estimate −$0.70, Reported −$0.76.

Maze Therapeutics' latest quarter

Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.

Questions

When does MAZE report earnings?

Maze Therapeutics is expected to report on Nov 9, 2026 (estimated).

What are analysts expecting from Maze Therapeutics?

EPS of −$0.75 for the quarter.

Does Maze Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 67% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.